An overview of the key trends shaping the pharmaceutical industry today, and those that are set to play a central role in the future, as companies transition towards a new business model: Pharma 2.0.
Provides key strategies and trends shaping the future of the pharmaceutical industry. Examines the impact of the Obama administration on US healthcare, and the implications for Pharma. Assesses the implications of the current economic and financial situation on healthcare. Analyzes key growth drivers and resistors set to shape Pharma\'s future.
Contact me at sosur@datamonitor.com to learn more!
A presentation I did for my Leadership and Special Topics in Pharmaceutical Marketing and Management class on social media. I completed this project with Tae Lee.
Introduction to the pharmaceutical market and practiceWayne Wei
As a lecturer for "Basic Principles of Drug Discovery and Development" for Department of Life Sciences, National Central of University for two years.
In charge of "Introduction to the pharmaceutical market and practice".
A presentation I did for my Leadership and Special Topics in Pharmaceutical Marketing and Management class on social media. I completed this project with Tae Lee.
Introduction to the pharmaceutical market and practiceWayne Wei
As a lecturer for "Basic Principles of Drug Discovery and Development" for Department of Life Sciences, National Central of University for two years.
In charge of "Introduction to the pharmaceutical market and practice".
This presentation provides a comprehensive overview of the current pharmaceutical industry. It begins with a look at some of the changes facing the industry and then moves into a discussion on digital technology and its impact on pharmaceutical companies. From there, the deck explores two digital trends, mobile and eDetailing. The presentation wraps up with some examples of pharmaceutical companies their digital presence.
Global pharmaceutical companies are modeled with a supply chain, which ensures that the right drug reaches the right people at the right time and in the right condition. The supply chain also ensures 100% product availability at optimum cost by carrying huge inventory, which maintains 100% fill rate. Manufacturers are trying to cut down development time to save costs. For example, a drug manufacturer who can trim development time by 19% can save up to USD 100 million. But if a drug is getting delayed to reach the market, the time delay costs the company around USD 1 million a day. So, pharmaceutical companies today are designing the supply chain to be as responsive as possible to reduce entry time to the market thereby increasing profit margins.
Thomas Müller, MD & Pharmacist, Head of Pharmaceuticals Dept Federal Joint Committee.
Pharma Pricing & Market Access Congress 2017
22 February 2017
London
Corporate Strategy Assignment - The Global Pharmaceutical IndustryAmany Hamza
This report provides an analytical strategic review of the global pharmaceutical industry. In the first part, it covers the external environment of the global pharmaceutical industry using PESTEL analysis and outlines the Key drivers for change. It then uses the Five Forces analysis to demonstrate the industry attractiveness. Secondly, we illustrate the strategic capabilities of Novartis using the Value chain. Finally, we attempt to highlights its financial performance, position and culture.
Information Management In Pharmaceutical IndustryFrank Wang
Pharmaceutical Industry Information Management Opportunities and Challenges in Research, Development, Clinical, Sales, Marketing, Managed Markets, Manufacturing, Supply Chain and Distribution
This research service provides an in-depth analysis of the global pharmaceutical contract manufacturing market with particular focus on the finished dose formulations such as solid, liquid and semi-solid, and injectable dose formulations. Segment analysis, trends and revenue forecast for the global, U.S. and European regions have been provided in detail. Strategic recommendations for the success of market participants have also been discussed.
Briefing based on the key findings of my research on the Global Generic Pharmaceuticals Market 2010, covering the developed markets like the U.S, Germany, UK, France, Italy and Spain as well as the emerging markets such as India and China.
Market Access - Getting ready for Personalized Medicine!executiveinsight
A presentation outlining the potential gains, pitfalls and strategies needed to realize the value in Personalized Medicine (Companion Diagnostics, Therapies).
Market access the challenges for medical devices Amy Morgan
With increased incidences of reimbursement rejections by payers and a growing usage of pricing and reimbursement tools market access is becoming increasingly restricted…
The U.S. Biopharmaceutical Industry (2014): Perspectives on Future Growth and...PhRMA
The capability to innovate is fast becoming the most important determinant of economic growth and a nation’s ability to compete and prosper in the 21st century global knowledge-based economy.
The innovative biopharmaceutical industry stands out among high-value knowledge-based industries, including aerospace, automotive, and semiconductors, as a driver for future U.S. economic growth. Aging populations throughout the world and rising purchasing power for medical advances among emerging economies are expected to drive increased demand for prescription medicines in the coming years, providing opportunities to increase production and exports.
This presentation was made in Pharmasource Munich 2012 and covers the aspects of Pharma API and Intermediate sourcing. The presentation covers the following sub topics
1. How the changing structure of the Pharma industry is affecting ingredients sourcing
2. Are India and China still the places to go ( and for how long) – does the Cost - Benefit stack –up?
3. Supplier Innovation and Potential gains
4. Analyzing the Asian Pharma market –
a generics hub with a competitive skill base
i may be contacted at gurmeetsingh144@hotmail.com
Over 30 years after the Orphan Drug Act was passed, orphan drugs continue to be a lucrative market for pharma companies. Although orphan diseases affect small populations, these treatments address a high unmet need and also benefit from commercially attractive pricing structures and additional regulatory benefits.
Full graphic: http://www.isrreports.com/free-resources/5408/
This presentation provides a comprehensive overview of the current pharmaceutical industry. It begins with a look at some of the changes facing the industry and then moves into a discussion on digital technology and its impact on pharmaceutical companies. From there, the deck explores two digital trends, mobile and eDetailing. The presentation wraps up with some examples of pharmaceutical companies their digital presence.
Global pharmaceutical companies are modeled with a supply chain, which ensures that the right drug reaches the right people at the right time and in the right condition. The supply chain also ensures 100% product availability at optimum cost by carrying huge inventory, which maintains 100% fill rate. Manufacturers are trying to cut down development time to save costs. For example, a drug manufacturer who can trim development time by 19% can save up to USD 100 million. But if a drug is getting delayed to reach the market, the time delay costs the company around USD 1 million a day. So, pharmaceutical companies today are designing the supply chain to be as responsive as possible to reduce entry time to the market thereby increasing profit margins.
Thomas Müller, MD & Pharmacist, Head of Pharmaceuticals Dept Federal Joint Committee.
Pharma Pricing & Market Access Congress 2017
22 February 2017
London
Corporate Strategy Assignment - The Global Pharmaceutical IndustryAmany Hamza
This report provides an analytical strategic review of the global pharmaceutical industry. In the first part, it covers the external environment of the global pharmaceutical industry using PESTEL analysis and outlines the Key drivers for change. It then uses the Five Forces analysis to demonstrate the industry attractiveness. Secondly, we illustrate the strategic capabilities of Novartis using the Value chain. Finally, we attempt to highlights its financial performance, position and culture.
Information Management In Pharmaceutical IndustryFrank Wang
Pharmaceutical Industry Information Management Opportunities and Challenges in Research, Development, Clinical, Sales, Marketing, Managed Markets, Manufacturing, Supply Chain and Distribution
This research service provides an in-depth analysis of the global pharmaceutical contract manufacturing market with particular focus on the finished dose formulations such as solid, liquid and semi-solid, and injectable dose formulations. Segment analysis, trends and revenue forecast for the global, U.S. and European regions have been provided in detail. Strategic recommendations for the success of market participants have also been discussed.
Briefing based on the key findings of my research on the Global Generic Pharmaceuticals Market 2010, covering the developed markets like the U.S, Germany, UK, France, Italy and Spain as well as the emerging markets such as India and China.
Market Access - Getting ready for Personalized Medicine!executiveinsight
A presentation outlining the potential gains, pitfalls and strategies needed to realize the value in Personalized Medicine (Companion Diagnostics, Therapies).
Market access the challenges for medical devices Amy Morgan
With increased incidences of reimbursement rejections by payers and a growing usage of pricing and reimbursement tools market access is becoming increasingly restricted…
The U.S. Biopharmaceutical Industry (2014): Perspectives on Future Growth and...PhRMA
The capability to innovate is fast becoming the most important determinant of economic growth and a nation’s ability to compete and prosper in the 21st century global knowledge-based economy.
The innovative biopharmaceutical industry stands out among high-value knowledge-based industries, including aerospace, automotive, and semiconductors, as a driver for future U.S. economic growth. Aging populations throughout the world and rising purchasing power for medical advances among emerging economies are expected to drive increased demand for prescription medicines in the coming years, providing opportunities to increase production and exports.
This presentation was made in Pharmasource Munich 2012 and covers the aspects of Pharma API and Intermediate sourcing. The presentation covers the following sub topics
1. How the changing structure of the Pharma industry is affecting ingredients sourcing
2. Are India and China still the places to go ( and for how long) – does the Cost - Benefit stack –up?
3. Supplier Innovation and Potential gains
4. Analyzing the Asian Pharma market –
a generics hub with a competitive skill base
i may be contacted at gurmeetsingh144@hotmail.com
Over 30 years after the Orphan Drug Act was passed, orphan drugs continue to be a lucrative market for pharma companies. Although orphan diseases affect small populations, these treatments address a high unmet need and also benefit from commercially attractive pricing structures and additional regulatory benefits.
Full graphic: http://www.isrreports.com/free-resources/5408/
The biotech industry is characterised by constant change and fast-paced growth. Keeping up with the rapid evolution is close to impossible. Nevertheless, that’s exactly what Niels Guldager, Senior Technology Partner within biopharmaceuticals, does best. In this slide series, he presents the top ten biotech trends as he sees them.
Immunotherapy Drugs Market PPT: Demand, Trends and Business Opportunities 202...IMARC Group
The global immunotherapy drugs market size reached US$ 195.4 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 327.8 Billion by 2028, exhibiting a growth rate (CAGR) of 8.9% during 2023-2028.
More Info:- https://www.imarcgroup.com/immunotherapy-drugs-market
From The Friengs To The Forefront mRAN is here to Transform Global HealthInsights10
Even though mRNA therapies have recently generated a lot of hype, few businesses have been able to advance their concepts and turn science into clinical reality. Vaccines have been used to prevent diseases including COVID-19, polio, and smallpox for ages. To get a report in detail, contact us at - info@insights10.com
Peripheral t cell Lymphoma Market 2023: Epidemiology, Industry Trends, Size, ...frankmorgan27
The peripheral T-cell lymphoma market is experiencing significant growth due to the rising prevalence of genetic mutations and chromosomal disorders causing uncontrolled lymphocyte proliferation.
Pneumonia Market 2024: Epidemiology, Industry Trends, Size, Share And Forecas...frankmorgan27
The Pneumonia market report thoroughly examines the market size, latest trends, and growth forecast. The report includes an overview of the disease and market scenario, as well as market trends, growth prospects, investment opportunities, and industry prospects. Additionally, it provides competitor analysis, regional analysis, and recent advancements in the Pneumonia market.
Pharmacogenomics market is projected to reach US$ 14,107.80 million by 2028 from US$ 7,087.81 million in 2021; it is expected to grow at a CAGR of 10.3% from 2021 to 2028
This report presents a strategic analysis of the Canada Dermatology
Prescription market and a forecast for its development in the medium
and long term. It provides a comprehensive overview of the market
value, dynamics, segmentation, characteristics, main players, trends and
insights, growth and demand drivers, challenges & future outlook, etc.
This is one of the most comprehensive reports about the Canada
Dermatology Prescription market, offering unmatched value, accuracy
and expert insights.
Visit https://insights10.com/ for more healthcare industry insights.
Connect with us @ info@insights10.com
Pharmacovigilance Market PPT 2022: Size, Growth, Demand and Forecast till 2027IMARC Group
The global pharmacovigilance market size reached US$ 6.7 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 11.8 Billion by 2027, exhibiting a CAGR of 10.5% during 2022-2027.
More Info:- https://www.imarcgroup.com/pharmacovigilance-market
Peptide Therapeutics Market by Product Type, Distribution Channel, End User 2...IMARC Group
The global peptide therapeutics market reached a value of US$ 35.9 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 61.9 Billion by 2027, exhibiting a CAGR of 9.42% during 2022-2027.
More Info:- https://www.imarcgroup.com/peptide-therapeutics-market
Key AI Trends Propelling a Sea Change in Post-pandemic careInsights10
Care delivery models are shifting paradigm shifts with the advent of novel technology solutions across the healthcare and life sciences industry. AI and ML applications are partly to take credit for this transformation which has facilitated the delivery of high-quality care services more conveniently. To get a report in detail, contact us at - info@insights10.com
The China Antiepileptic Drug market size stood at around USD XX billion in 2019 and is projected to reach USD 1.16 billion by 2028, exhibiting a CAGR of XX% during the forecast period.
The prevalence of epilepsy in China is 7%, and the prevalence of active epilepsy is 4.6%. In addition, there is a large gap in the treatment of epilepsy, which is about 63%. Based on this, it is estimated that the current epilepsy number of patients is more than 9 million, of which more than 6.4 million are patients with active epilepsy.
Market Drivers
Increasing incidence of neurological disorder and rising geriatric population are some factors driving the growth of Antiepileptic drugs market. Increasing advancement of drug modification and increasing number of available Antiepileptic drugs are some factors driving the growth of the market. Moreover, advancement in drugs provide small effects on liver metabolism that converts into a lower rate of side effects further contributing to the growth of Antiepileptic Drugs Market. Active government support and Investments are expediting the market growth. The R&D is now focused on the development of target specific drugs.
Visit https://insights10.com/ for more healthcare industry insights.
Connect with us @ info@insights10.com
Companion Diagnostics Market PPT: Growth, Outlook, Demand, Keyplayer Analysis...IMARC Group
The global companion diagnostics market size reached US$ 5.0 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 11.7 Billion by 2027, exhibiting a growth rate (CAGR) of 14.78% during 2022-2027.
More Info:- https://www.imarcgroup.com/companion-diagnostics-market
Patient Engagement Solutions Market by Product Type, Distribution Channel, En...IMARC Group
The global patient engagement solutions market size reached US$ 35.6 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 132.2 Billion by 2032, exhibiting a growth rate (CAGR) of 15.2% during 2024-2032.
More Info:- https://www.imarcgroup.com/patient-engagement-solutions-market
Digital therapeutics market is expected to grow from US$ 4,226.94 million in 2021 to US$ 18,061.79 million by 2028; it is estimated to grow at a CAGR of 23.1% from 2021 to 2028
Intratumoral Cancer Therapies Market 2023: Epidemiology, Industry Trends, Siz...frankmorgan27
The elevating prevalence of cancer and the inflating need for therapies that can deliver drugs directly to the tumor site, enabling the targeted treatment, are primarily stimulating the intratumoral cancer therapies market.
Pompe Disease Treatment Market Growth, Demand and Challenges of the Key Indus...IMARC Group
The global Pompe disease treatment market size reached US$ 1.0 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 1.3 Billion by 2032, exhibiting a growth rate (CAGR) of 2.58% during 2024-2032.
More Info:- https://www.imarcgroup.com/pompe-disease-treatment-market
PPT: Medical Cyclotron Market to Witness Huge Growth during 2022-2027IMARC Group
According to the latest report by IMARC Group, the global medical cyclotron market reached a value of US$ 192.6 Million in 2021. Medical cyclotron represents a type of particle accelerator, wherein an alternating electric field propels a beam of charged units in a spiral pattern. This assists in producing protons and radioactive isotopes for medical imaging, diagnosis, and treatment of various cardiovascular disorders.
Similar to Future Pharma Trends - Long-term opportunities tempered by short-term challenges (20)
PPT: Medical Cyclotron Market to Witness Huge Growth during 2022-2027
Future Pharma Trends - Long-term opportunities tempered by short-term challenges
1. www.datamonitor.com
Datamonitor America
245 Fifth Avenue
4th Floor
New York, NY 10016
USA
t: +1 212 686 7400
f: +1 646 365 3362
e: usinfo@datamonitor.com
Datamonitor Europe
Charles House
108-110 Finchley Road
London NW3 5JJ
United Kingdom
t: +44 20 7675 7000
f: +44 20 7675 7500
e: eurinfo@datamonitor.com
Datamonitor Asia Pacific
Level 46 / 2 Park Street
Sydney
NSW 2000
Australia
t: +61 2 8705 6900
f: +61 2 8705 6901
e: apinfo@datamonitor.com
Datamonitor Japan
Da Vinci Ginza East 7th Floor
5-14-5 Ginza
Chuo-ku
Tokyo 104-0061
Japan
t: +81 3 5148 7670
f: +81 3 4496 4316
e: jpinfo@datamonitor.com
Future Pharmaceutical
Industry Trends
Long-term opportunities tempered by short-term
challenges
In recent years, Pharma has begun to adapt its business model in response to growing
industry constraints and the decline of the primary-care focused blockbuster therapy. This
process of change has recently been disrupted by unprecedented challenges caused by the
global economic downturn, and by President Obama’s planned overhaul of the US healthcare
system.
To continue on its journey towards Pharma 2.0, Pharma needs to balance the more pressing
short-term issues against the longer-term trends shaping the industry.
Reference Code: DMHC2497
Publication Date: 03/2009